Armata Pharmaceuticals, Inc. (ARMP) Form 10-Q — May 13, 2026
Armata Pharmaceuticals, Inc. (ARMP) reported a net loss of $115.3 million for the three months ended March 31, 2026, a significant increase from the $6.5 million loss in the same period of 2025. The loss was primarily driven by a $101.1 million loss from the change in fair value of the Convertible Loan, which was accounted for at fair value. The company's cash and cash equivalents as of March 31, 2026, were $4.8 million, down from $8.7 million at the end of 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 789
- Total Debt
- 381386
- Debt Amount
- 254922
- Revenue Yoy
- 60.7
- Total Assets
- 69800
- Cash Position
- 4754
- Deal Value Usd
- 0
- Interest Rate
- 14
- Maturity Date
- January 11, 2029
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 36530284
- Debt discount
- 20640
Price after filing
1 day: -7.0%7 days: -7.9%30 days: -15.3%
Close on the filing date to close N calendar days later (from $8.82). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.